A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study

Ting Deng, Kaijiang Liu, Liang Chen, Xiaojun Chen, Hua Wen Li, Hongyan Guo, Huijiao Zhang, Libing Xiang, Xin Feng, Xiaoyu Wang, Hys Ngan, Jianguo Zhao, Dongling Zou, Qing Liu, Jihong LiuJournal of Gynecologic Oncology 2023 · DOI

Abstract

Background: The Lymphadenectomy in Ovarian Neoplasms (LION) study revealed that systemic lymphadenectomy did not bring survival benefit for advanced ovarian cancer patients with clinically normal lymph nodes and was associated with a higher incidence of operative complications. However, there is no consensus on whether lymphadenectomy has survival benefit or not in early epithelial ovarian cancer (EOC).

Methods: We designed the LOVE study, a multicenter, randomized controlled, phase III trial to compare the efficacy and safety of comprehensive staging surgery with or without lymphadenectomy in stages IA-IIB EOC and fallopian tube carcinomas (FTC). The hypothesis is that the oncological outcomes provided by comprehensive staging surgery without lymphadenectomy are non-inferior to those of conventional completion staging surgery in early-stage EOC and FTC patients who have indications for post-operative adjuvant chemotherapy.

Introduction

Epithelial ovarian cancer (EOC) remains the most lethal gynecological malignancy. While often diagnosed at an advanced stage, approximately 30% of cases are identified in early stages (IA–IIB). The current surgical standard for these patients involves systematic pelvic and para-aortic lymphadenectomy for staging purposes. However, this procedure is technically demanding and associated with significant risks, including major hemorrhage, nerve injury, and chronic lymphedema.

Recent findings from the LION study indicated that for advanced ovarian cancer, removing clinically normal lymph nodes provided no survival benefit while increasing surgical morbidity. The LOVE study addresses the lack of high-quality, prospective evidence for early-stage patients, investigating whether omitting systematic lymphadenectomy is non-inferior to the traditional approach in patients already requiring adjuvant chemotherapy.

Methods and Study Design

The LOVE study (NCT04710797) is a prospective, open-label, randomized, phase III non-inferiority trial. The study aims to recruit 656 patients across multiple top-tier hospitals in China.

Study design and protocol for the LOVE trial, including inclusion criteria and randomization groups.

Participants and Randomization

Patients with stage IA–IIB EOC or fallopian tube carcinomas (FTC) who have indications for chemotherapy are randomized 1:1 into two groups:

  1. Experimental Group: Comprehensive staging surgery without lymphadenectomy.
  2. Comparative Group: Standard staging surgery including systematic pelvic and para-aortic lymphadenectomy (minimum of 20 pelvic and 10 para-aortic nodes).

Treatment and Endpoints

All subjects receive 3–6 cycles of standard adjuvant chemotherapy (typically paclitaxel and carboplatin). The primary endpoint is disease-free survival (DFS) over five years. Secondary endpoints include overall survival (OS), the rate of retroperitoneal nodal recurrence, and Quality of Life (QOL) assessments.

Key Hypotheses

The central premise of the LOVE study is the "Chemotherapy Buffer" hypothesis: for patients already requiring systemic chemotherapy, the treatment likely eliminates microscopic disease in lymph nodes, potentially rendering the surgical trauma of lymphadenectomy redundant. The study utilizes a non-inferiority design with a 10% tolerance margin to determine if the less invasive approach can reduce treatment toxicity without compromising oncological outcomes.

Expected Outcomes and Limitations

As a protocol paper, final results are pending. Based on historical data, the researchers expect a 5-year DFS of 80%. The study opened in February 2021 with a planned duration of five years.

Potential limitations include surgical variability across centers and the risk of "up-staging." By omitting node removal, some patients might be under-staged (e.g., Stage IIIA1), potentially affecting access to specific maintenance therapies like PARP inhibitors. Additionally, the study does not currently stratify by histological subtype, which may influence response to treatment.

Conclusion

The LOVE study represents a critical step toward de-escalating surgical treatment in early-stage ovarian cancer. If non-inferiority is proven, it could lead to a significant shift in international guidelines, sparing patients from unnecessary surgical morbidity while maintaining survival standards.

Summary updated

Abstract

Background:The Lymphadenectomy in Ovarian Neoplasms (LION) study revealed that systemic lymphadenectomy did not bring survival benefit for advanced ovarian cancer patients with clinically normal lymph nodes and was associated with a higher incidence of operative complications.However, there is no consensus on whether lymphadenectomy has survival benefit or not in early epithelial ovarian cancer (EOC).Methods: We designed the LOVE study, a multicenter, randomized controlled, phase III trial to compare the efficacy and safety of comprehensive staging surgery with or without lymphadenectomy in stages IA-IIB EOC and fallopian tube carcinomas (FTC).The hypothesis is that the oncological outcomes provided by comprehensive staging surgery without lymphadenectomy are non-inferior to those of conventional completion staging surgery in early-stage EOC and FTC patients who have indications for post-operative adjuvant chemotherapy.Patients assigned to experimental group will undergo comprehensive staging surgery, but lymphadenectomy.Patients assigned to comparative group will undergo completion staging surgery including systematic pelvic and para-aortic lymphadenectomy.All subjects will receive 3-6 cycles of standard adjuvant chemotherapy.Major inclusion criteria are pathologic confirmed stage IA-IIB EOC or FTC, and patients have indications for adjuvant chemotherapy either confirmed by intraoperative fast frozen section or previous pathology after an incomplete staging surgery.Major exclusion criteria are non-epithelial
BibTeX
@article{deng2023prospective,
  author = {Ting Deng and Kaijiang Liu and Liang Chen and Xiaojun Chen and Hua Wen Li and Hongyan Guo and Huijiao Zhang and Libing Xiang and Xin Feng and Xiaoyu Wang and Hys Ngan and Jianguo Zhao and Dongling Zou and Qing Liu and Jihong Liu},
  title = {{A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study}},
  journal = {Journal of Gynecologic Oncology},
  year = {2023},
  doi = {10.3802/jgo.2023.34.e52},
}
Figure